PRF1 and neoplasm: The mechanism of action of CAR T-cell involve the binding of CARs to a targeted antigen present on tumor cell surface via scFV recognition domain, which elicit anti-tumoral effects through the secretion of inflammatory cytokines (e.g., IL-2, IFN-γ, and TNF-α), cytolytic effector function via perforin and granzyme (Benmebarek et al., 2019), TNF-related apoptosis-inducing ligand (TRAIL), which binds to death receptors (e.g., DR4 and DR5) on tumor cells cell surface to activate graft-versus tumor effect (donor T-cells) (Watanabe et al., 2021).